May I, 2024

Trials in small cell lung cancer and non–small cell lung cancer are fueling excitement in the oncology community.

Pembrolizumab with chemotherapy led to a positive trend in overall survival among patients with endometrial cancer.

TNO155 combined with either spartalizumab or ribociclib showed acceptable safety and tolerability across solid tumors in a phase 1b open-label study.

According to a recent analysis, preliminary circulating tumor DNA kinetics could serve as an early pharmacodynamic biomarker, offering potential for early biologic proof of concept.

In a phase 1/2 trial of NT219 with cetuximab in patients with squamous cell carcinoma of the head and neck, safety and tolerability responses were encouraging.

Decentralized clinical trials represent a promising approach to clinical research that can improve patient access to new treatments while streamlining the development process.

A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.

Due to federal budget constraints, the National Cancer Institute faces significant risk, impacting cancer research funding amid crucial breakthroughs.